home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

    Jan 16, 2020

    Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufac...


    READ MORE

    /news-article.aspx?ID=36303630

    NEW VETERINARY MEDICINES REGULATION

    Jan 16, 2020

    A new Veterinary Medicines Regulation (Regulation (EU) 2019/6) has been introduced to modernise the existing rules on the authorisation and use of veterinary medicines in the European Union (EU). This becomes applicable on 28 January 2022. The regulation contains new measures for increasing the avai...


    READ MORE

    /news-article.aspx?ID=36313631

    OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

    Jan 16, 2020

    In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Opt...


    READ MORE

    /news-article.aspx?ID=36323632

    GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

    Jan 14, 2020

    The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England an...


    READ MORE

    /news-article.aspx?ID=36273627

    POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

    Jan 14, 2020

    The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap o...


    READ MORE

    /news-article.aspx?ID=36283628

    ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

    Jan 14, 2020

    Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS ...


    READ MORE

    /news-article.aspx?ID=36293629

    FIVE WAYS PHARMA IS LEVERAGING DIGITAL THERAPEUTICS TO DEMONSTRATE VALUE TO HEALTH PLANS

    Jan 10, 2020

    Some estimates now put the cost of developing a new drug at nearly $2.9 billion. Adding to this financial pressure, pharmaceutical companies have little control over what CMS, health plans and PBMs will agree to pay for approved drugs, or if their new drugs will be listed on formularies—often ...


    READ MORE

    /news-article.aspx?ID=36243624

    NEW UNDERSTANDING OF ANTIBIOTIC SYNTHESIS

    Jan 10, 2020

    Researchers at McGill University's Faculty of Medicine have made important strides in understanding the functioning of enzymes that play an integral role in the production of antibiotics and other therapeutics. "Many of the medicines that we rely on today are natural products, made by the E...


    READ MORE

    /news-article.aspx?ID=36253625

TRENDING NEWS


    ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

    Feb 13, 2020

    Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of a...


    READ MORE

    /news-article.aspx?ID=36573657

    NOVARTIS DEMANDS OUTSIDE COUNSEL MAKE TOUGH DIVERSITY GUARANTEES

    Feb 13, 2020

    Novartis AG is demanding that its 22 “preferred” Big Law firms make specific diverse staffing commitments for each engagement with the pharma giant or face punishment in the form of reduced payments. Through the new program announced on Wednesday, Novartis is also requiring its outside c...


    READ MORE

    /news-article.aspx?ID=36583658

    HUATENG PHARMA DEVELOPS SPRAY AGAINST NEW CORONAVIRUS INFECTION

    Feb 11, 2020

    This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attentio...


    READ MORE

    /news-article.aspx?ID=36543654

    PATIENT SUCCESSFULLY TREATED FOR CORONAVIRUS IN THE US

    Feb 11, 2020

    The Ebola drug Remdesivir, made by Gilead Sciences, was given to an American who is 35 years old. The doctors reported that on 26 January his condition seemed to improve within a day, and by 30 January it had resolved most of the symptoms except a cough. However, Gilead feel this is not conclusive p...


    READ MORE

    /news-article.aspx?ID=36553655

    DURHAM’S MYCOVIA PHARMA EXTENDS CLINICAL TRIAL OF ANTI-FUNGAL DRUG FOR YEAST INFECTIONS

    Feb 11, 2020

    Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT...


    READ MORE

    /news-article.aspx?ID=36563656

    AS ADCETRIS SLOWS, SEATTLE GENETICS TOUTS EARLY LAUNCH FIGURES FOR BLADDER CANCER MED PADCEV

    Feb 07, 2020

    It wasn’t long ago when Seattle Genetics shareholders moved past earlier letdowns and cheered strong performance from key cancer drug Adcetris. But now, they might be disappointed again. During the fourth quarter, Adcetris pulled in sales of $166.2 million in the U.S. and Canada, a 26% increas...


    READ MORE

    /news-article.aspx?ID=36513651

    CORONAVIRUS DRAWS ATTENTION TO FDA OVERSIGHT OF CHINESE DRUGS

    Feb 07, 2020

    Lawmakers are raising concerns anew about the U.S. reliance on foreign drug manufacturing amid the Wuhan coronavirus outbreak that has pushed FDA inspectors out of China. The novel disease outbreak could spark medical product shortages if the epidemic is not resolved swiftly, experts say. The challe...


    READ MORE

    /news-article.aspx?ID=36523652

    CORONAVIRUS: THE LATEST PROBLEM BIG PHARMA WON’T SOLVE

    Feb 07, 2020

    Time for new pharmaceutical-innovation models. The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year, the four drug companies that dominated the vaccine market made $30 billion selling vaccines. The pharmaceutical industr...


    READ MORE

    /news-article.aspx?ID=36533653

    MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

    Feb 05, 2020

    Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 pe...


    READ MORE

    /news-article.aspx?ID=36483648

    SMALL MOLECULES LEAD IN RECENT NEW DRUG APPROVALS

    Feb 05, 2020

    Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules...


    READ MORE

    /news-article.aspx?ID=36493649

    GILEAD JOINS GSK, J&J IN OFFERING CORONAVIRUS VACCINE OPTIONS

    Feb 05, 2020

    With the death toll in China topping 425, the coronavirus, now officially classified as a global health threat by the World Health Organisation (WHO), is showing no signs of slowing down. More than 20,000 cases have been confirmed around the world, with more than 20 nations reporting cases – s...


    READ MORE

    /news-article.aspx?ID=36503650

    GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

    Feb 03, 2020

    Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in...


    READ MORE

    /news-article.aspx?ID=36463646

    ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

    Feb 03, 2020

    Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause mor...


    READ MORE

    /news-article.aspx?ID=36473647

    J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

    Jan 30, 2020

    The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - th...


    READ MORE

    /news-article.aspx?ID=36433643

    INSURERS TAKE AIM AT BIG PHARMA. THIS SMALL-CAP STOCK STANDS TO WIN.

    Jan 30, 2020

    The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. T...


    READ MORE

    /news-article.aspx?ID=36443644

    ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

    Jan 30, 2020

    Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also mar...


    READ MORE

    /news-article.aspx?ID=36453645

SPOTLIGHT

From passive consumer to active participant, the role of the patient is changing as dramatically as the healthcare system itself. The fee-for-service, volume-based care of the past is giving way to a value-based care system focusing on quality and outcomes. The newsystem seeks to reduce skyroc

RESOURCES

Events